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Abstract
Background: Tumor suppressor gene (TSG) RASSF1A and candidate TSG BLU are two tandem head-to-tail genes located at
3p21.3. We hypothesized that there may be a concordance on their gene expression and promoter methylation status. If
not, then there may be an insulator located between RASSF1A and BLU genes that provides a barrier activity.
Methodology/Principal Findings: We first identified potential transcriptionally important CpG sites using the methylation-
specific oligonucleotide array in relation to mRNA expression of RASSF1A and BLU genes in primary lung tumors. We
demonstrated that E2F1 bound to the potential transcriptionally important CpG sites in RASSF1A gene of a normal lung cell
line expressing RASSF1A transcripts, whereas loss of E2F1 binding to RASSF1A in A549 cancer cell line was the result of DNA
methylation. Both RASSF1A and BLU genes had their own potential transcriptionally important CpG regions. However, there
was no correlation of methylation status between RASSF1A and BLU. Using gel shift assay and chromatin
immunoprecipitation-PCR (ChIP-PCR), we found that CCCTC-binding factor (CTCF) bound to insulator sequences located
between these two genes. Bisulfite sequencing and ChIP-PCR revealed distinct methylation and chromatin boundaries
separated by the CTCF binding domains in normal cells, whereas such distinct epigenetic domains were not observed in
cancer cells. Note that demethylation reagent and histone deacetylase inhibitor treatments led to CTCF binding and
recovery of barrier effect for RASSF1A and BLU genes in cancer cells.
Conclusions/Significance: Our study dissects the potential transcriptionally important CpG sites for RASSF1A and BLU genes
at the sequence level and demonstrates that CTCF binding to the insulator of BLU gene provides a barrier activity within
separate epigenetic domains of the juxtaposed BLU and RASSF1A loci in the 3p21.3 gene cluster region.
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Introduction
Molecular changes in oncogenes and tumor suppressor genes
(TSGs)areinvolvedintumorigenesis[1,2].TheTSGsareinactivated
by geneticandepigenetic abnormalities, includingdeletion,mutation,
promoter hypermethylation, abnormal histone modifications and loss
of heterozygosity, [3,4,5]. Allelic loss of chromosome 3p21.3 is the
most frequent genetic alteration in many sporadic cancers, including
hepatocellular carcinomas, gallbladder carcinoma, and breast cancer
[6,7,8]. In our previous study, the region in 3p21 showed more than
50% loss of heterozygosity in 71 microdissected tumors of primary
non-small cell lung cancer (NSCLC) patients compared with their
matched normal lung tissues [9]. These data suggested that allelic loss
in 3p21.3 and the inactivation of genes in this locus were involved in
lung tumorigenesis.
The loss of function of several genes at 3p21.3 such as Ras
association (RalGDS/AF-6) domain family 1 isoform A (RASSF1A) and
zinc finger, MYND-type containing 10 (ZMYND10/BLU) has been
reported in distinct human carcinomas [7,8]. RASSF1A
(NM_007128) is a TSG that encodes a member of the RAS
effector family which regulates cell proliferation and apoptosis
[10]. RASSF1A and Ras association (RalGDS/AF-6) domain
family member 5 (RASSF15/NORE1A) form complexes with
mammalian sterile 20 kinases 1 (MST1) or with connector
enhancer of KSR 1 (CNK1) and Modulator of Apoptosis-1
(MOAP1) to modulate apoptosis [11,12,13]. Song et al. reported
that RASSF1A inhibited the APC-Cdc20 complex and promoted
mitotic arrest at pro-metaphase [14]. However, Liu et al. de-
monstrated that the interaction between RASSF1A and Cdc20
was complex [15]. In addition, RASSF1A and RASSF1C
regulated microtubule polymerization and potentially affected
the maintenance of genomic stability [16,17]. Re-expression of
RASSF1A reduced colony-formation ability in a glioma cell line
[18]. Hypermethylation of the RASSF1A promoter is frequently
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bladder, neuroblastoma, medulloblastoma, and gliomas tumors
[19]. Hypermethylation reduces the transcription and translation
of modified genes. Furthermore, RASSF1A methylation correlated
with poor survival in lung cancer patients [20,21].
BLU (NM_015896) has homology to the MTG/ETO family of
transcription factors. Exogenous expression of BLU in lung cancer
or neuroblastoma cell lines reduced efficiency of colony formation
in vitro [3]. BLU also functionally suppresses tumor formation in
nude mice [22]. Down-regulation of BLU RNA expression was
observed in nasopharyngeal carcinoma (NPC) cell lines (83%) and
NPC biopsies (80%) [22]. BLU promoter is commonly hyper-
methylated in cancers such as glioma, cervical squamous cell
carcinomas, NPC, neuroblastoma, and NSCLC [23]. BLU is a
stress-responsive gene regulated by E2F1, but hypermethylation
impairs this response [24].
RASSF1A and BLU gene loci are located next to each other in
the region 3p21.3. Their CpG island hypermethylation and
expression status is similar in NSCLC patients [3]. In contrast,
other studies report no correlation of hypermethylation of
RASSF1A and BLU promoters in NPC, gliomas, and lung cancer
patients [18,24,25]. However, the promoters of RASSF1A and BLU
have never been examined in the same series of lung cancer
patients for regional signals that modulate protein/RNA expres-
sion levels and promoter methylation status. We hypothesized that
RASSF1A and BLU exhibits similar gene expression and promoter
methylation status in tumors. If not, then an insulator may exist
between RASSF1A and BLU genes to provide a barrier activity. In
the present study, we identified potential transcriptionally
important CpG sites using the methylation-specific oligonucleotide
(MSO) array method and characterized E2F1 binding to the
potential transcriptionally important CpG sites. Second, we
demonstrated that CCCTC-binding factor (CTCF) bound to
insulators and exhibited barrier activity between RASSF1A and
BLU promoters. These data provided a mechanism for disparate
methylation status and expression levels of these two closely
located genes. Our data provided evidence that both genes possess
their own potential transcriptionally important CpG regions. DNA
methylation and transcription of RASSF1A and BLU promoters are
independently controlled within separate epigenetic domains.
Materials and Methods
Cell lines and culture conditions
Human normal lung cell lines, IMR90 and MRC5, (American
Type Culture Collection, ATCC) and human lung cancer cell
lines, A549 and H1299 (ATCC), and CL1-0, CL1-1 and CL1-5
(obtained from Dr. Pan-Chyr Yang, Department of Internal
Medicine, National Taiwan University Hospital, Taipei, Taiwan)
were cultured in DMEM medium (GIBCO, Grand Island, N.Y.)
containing 10% fetal bovine serum (FBS) (BIOCHROM AG,
Leonorenstr, Berlin) and 1% penicillin-streptomycin (GIBCO) and
incubated at 37uCi n5 %C O 2 atmosphere.
Clinical sample preparation and DNA/RNA extraction
Tissues were collected after obtaining appropriate institutional
review board permission from Taipei Veterans General Hospital
and written informed consent from the recruited patients.
Surgically resected tumor tissue and corresponding normal tissue
were collected from 76 patients diagnosed with primary NSCLC
admitted to Veterans General Hospital, Taipei. Of these patients,
55 had adenocarcinomas (AD), 18 had squamous cell carcinomas
(SCC), and 3 had large cell carcinomas (LC). Histological
classification was determined according to the WHO classification
and the tumor-node-metastasis system. Information on the age,
sex, and smoking history of the patients was obtained from hospital
records. The genomic DNA was prepared using proteinase K
digestion and phenol-chloroform extraction. Total RNA was
prepared from tumors and normal lung tissues using TRIzol
reagent (Invitrogen, Carlsbad, CA). cDNA was synthesized using
SuperScript reverse transcriptase (Invitrogen).
Semiquantitative multiplex reverse transcription-PCR
(RT-PCR) assay and quantitative RT-PCR (qRT-PCR)
RASSF1A and BLU mRNA expression was assayed in a semi-
quantitative multiplex RT-PCR and quantitative RT-PCR (qRT-
PCR) analysis using the GAPDH gene as an internal control. The
RT-PCR condition was optimized by adopting the minimal cycle
number to avoid a saturation problem. The primer nucleotide
sequences, annealing temperature, and PCR cycle number are
shown in the Table S1. RT-PCR products were separated on
1.5% agarose gels and visualized under UV illumination. To
quantify the relative levels of mRNA expression in the multiplex
RT-PCR assay, the value of the GAPDH in each reaction was used
as the baseline gene expression of that sample and relative value
was calculated for the RASSF1A and BLU genes for each tumor
and matched normal samples. Tumor cells that exhibited mRNA
expression below normal cells were considered to have an
abnormal pattern. qRT-PCR was performed with the KAPA
SYBR FAST Universal 2X qPCR Master (Kapa Biosystems,
Woburn, MA) in a 20 ml final volume in a Rotor Gene 3000 Real-
Time PCR Machine (Qiagen, Valencia, CA). Real-time PCR
conditions were as follows: 95uC for 10 min, followed by 40 cycles
of 95uC, 20 sec; 60uC, 20 sec; and 72uC, 20 sec. Data were
normalized with GAPDH expression as internal controls.
Bisulfite modification and methylation-specific
oligonucleotide (MSO) array
Tumor DNA from 32 patients (23 were AD, 8 were SCC, and
1 was LC) was analyzed by MSO array. To prepare the
methylation-positive DNA, DNA was treated with M. SssI
methyltransferase (New England Biolabs, Beverly, MA) that
methylates all cytosine residues of CpG dinucleotides in the
genome. The test samples and SssI-treated DNA samples were
treated with sodium bisulfite as previously described [26]. Pre-
paration of MSO arrays was carried out essentially as described
previously [27]. The oligonucleotides and PCR primers for
RASSF1A methylation assay were described previously [28].
Twenty sets of paired oligonucleotides were designed to include
the promoter and first exon of BLU CpG sites. The location of
MSO probes for RASSF1A and BLU was shown in Fig. 1A. For
DNA target preparation, bisulfite-treated DNA was amplified
from promoter to the first exon regions located in the CpG island
using primers listed in Table S1. To control the accuracy and
reproducibility of the MSO probes, a series of MSO hybridiza-
tion were performed with mixed samples containing 100, 66, 33,
and 0% SssI-treated methylation-positive DNA [27]. Standard-
ization curves generated with these optimal probe sets were
subsequently used to investigate RASSF1A and BLU methylation
in the test tumor DNA samples [27]. Array slide hybridization
and wash were described in the previous study [26,27].
Representative figures were shown in the Fig. S1. The array
slides were scanned with a GenePix 4000A scanner (Axon
Instruments). MSO data were normalized according to a global
ratio in each array image, and the intensity ratio of M/(M+U)
(M: methylated probe; U: unmethylated probe) for each probe set
was then derived.
RASSF1A & BLU in Lung Cancer
PLoS ONE | www.plosone.org 2 September 2010 | Volume 5 | Issue 9 | e12847Figure 1. Determination of methylation status of RASSF1A and BLU CpG sites by MSO array. (A) Genomic map of the RASSF1A and BLU CpG
sites detectedbyMSOwere indicated by thin verticalbars. PutativeE2F1 binding sites aremarked with black boxes. Star symbols indicatedthepotential
transcriptionally important CpG sites. The locations of MSO probe were shown in black horizontal lines. The numbered probes indicated the potential
transcriptionally important CpG sites. Blue horizontal lines indicated the regions amplified in the ChIP-PCR assay to detect E2F binding. MSP primers for
RASSF1A (MSP1 and MSP2) and BLU were designed to analyze the methylation status of E2F1 binding sites. (B) MSO results are presented for 32 primary
lung tumors (left column) in the RASSF1A potential transcriptionally important CpG sites (shown in the first row). The patients were then ranked by
averagemethylationpercentagedeterminedbyMSOmethod.Theaveragemethylationpercentageofthepotentialtranscriptionallyimportant CpGsfor
each patient was listed in the second to the last (right) column. The relative mRNA expression level was calculated for each tumor (T) and matched
normal (N) samples and was indicated by RT (T/N) in the right column. The extent of methylation of each CpG was indicated by blue color shown in the
lower right corner. The darker shades of blue indicated increasing methylation. (C) MSO results were presented for 32 primary lung tumors in BLU
potential transcriptionally important CpG sites. The heavily methylated and lightly methylated samples were separated by a cut-off line for the RASSF1A
and BLU genes. The cut-off value is determined by the mean methylation percentage of potential transcriptionally important CpG sites.
doi:10.1371/journal.pone.0012847.g001
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The methylation status in the E2F1 binding sites of the
RASSF1A and BLU promoters were determined by chemical
treatment with sodium bisulfite and subsequent methylation-
specific PCR (MSP) analysis. EZ DNA Methylation-Gold
TM Kit
(Zymo Research, Orange, CA) was used for bisulfite conversion of
DNA. MSP analyses used the primers for the –144 to –38 bp
(MSP1) and 26t o+94 bp (MSP2) regions in RASSF1A promoter,
as well as exon1 and 2156 to +1 bp region in the BLU promoter
designing at putative E2F1 binding sites as shown in Fig. 1A. The
primer nucleotide sequences, annealing temperature, and PCR
cycle number were listed in Table S1. Positive control samples of
unmethylated MRC5 normal lung cell DNA and SssI methyl-
transferase treated methylated DNA were also included for each
set of PCR.
Bisulfite DNA sequencing analysis
The methylation status of the upstream and downstream CTCF
regions was examined after bisulfate modification by sequencing
analysis. Bisulfite sequencing was conducted for a fragment of
chromosome 3 genomic contig (NW_001838877). Primers were
designed for CpG sites 260 to +14 (corresponding to nucleotide
numbers from 22314 to +137 bp) in which the first CpG site was
defined as +1 which corresponded to RASSF1A transcriptional
start site. Bisulfite-modified DNA was amplified using four pairs of
primers: BS-P1, BS-P2, BS-P3, and BS-P4 shown in Table S1.
The products were isolated and sub-cloned into the pCR2.1-
TOPO vector (Invitrogen), and five individual clones per each
sample were sequenced.
Immunohistochemistry (IHC) assay
Paraffin blocks of tumors were dissected into 5-mm slices and
processed using standard deparaffinization and rehydration
techniques. Monoclonal antibody for anti-RASSF1A (1:500;
eBioscience, San Diego, CA), and polyclonal antibody for anti-
BLU (1:100; Abcam, Cambridge, UK) were used as the primary
antibodies to detect RASSF1A and BLU protein expression,
respectively. The evaluation of the immunohistochemistry was
conducted without prior knowledge of the clinical and pathologic
characteristics of the cases (blinded). RASSF1A and BLU were
graded as low or negative expression when tumor cell staining was
,20% and ,40%, respectively. The surrounding normal stroma
and epithelial cells served as an internal positive control for each
slide. Normal lung tissue slide from some patients were included to
evaluate the IHC results.
DNA demethylation, histone deacetylation and CTCF
transfection
H1299 cells (10
6) were treated with the demethylating agent 59-
AZA-29-deoxycytidine (AZA) at 10 mM for 24 hours. The medium
was then replaced with medium containing 10 mM AZA and
0.5 mM HDAC inhibitor Trichostatin A (TSA) for 24 hours. After
washing with PBS and replacing growth medium, the cells were
transfected with pCMV-SPORT6-CTCF expression vector (Open
Biosystems, Huntsville, AL) using ExGen 500 in vitro transfection
reagent (Fermentas, Glen Burnie, Maryland) after AZA and TSA
treatments. Samples were incubated for 96 hours and cells were
collected for ChIP analysis.
Chromatin immunoprecipitation (ChIP) and target region
ChIP-PCR
Cells were grown on a 100620-mm culture dish to approx-
imately 80–90% confluency, cross-linked with 1% formaldehyde
for 10 min at 37uC, and stopped by the addition of glycine to a
final concentration of 0.125 M. Lysates were sonicated using
Bioruptor
TM system (Diagenode, Lie `ge, Belgium) to shear DNA to
lengths between 200 and 800 bp. Subsequent steps were
performed with the ChIP assay kit (Upstate Biotechnology, Lake
Placid, NY, USA) according to the manufacturer’s instructions.
ChIP was performed using anti-acetylated lysine 9 of histone H3
(K9Ac) (1:400; Upstate Biotechnology), anti-trimethylted lysine 27
of histone H3 (K27M) (1:400; Upstate Biotechnology), anti-E2F1
(1:500; Active Motif), and anti-CTCF (1:500; Upstate Biotechnol-
ogy) antibodies for 16 hours at 4uC. De-crosslinks and purification
of immunoprecipitated DNA were performed with the ChIP assay
kit (Upstate Biotechnology). The ChIP experiments were repeated
three times.
Conditions of PCR analysis with optimized cycle number,
primer pairs for RASSF1A, BLU, GAPDH and c-Myc promoters,
CTCF binding domains, and regions next to CTCF binding
domain were listed in Table S1.
Electrophoretic mobility shift assay (EMSA)
The CTCF binding sites were predicted from the CTCF
binding site database (CTCFBSDB) (http://insulatordb.utmem.
edu), and three putative CTCF binding sites were identified in
exon 7 (CTCF-1), intron 8 (CTCF-2), and intron 11 (CTCF-3) of
BLU gene. The probes of CTCF binding sites for the genome
sequence of the BLU gene were as follows: CTCF-1, +2751 to
+2777 bp; CTCF-2, +3555 to +3579 bp; and CTCF-3, +4226 to
+4251 bp, and probe sequences were listed in Table S1. A549 cells
were transfected with complete CTCF (accession no. BC014267)
containing pcDNA3.1 vector for 48 hrs. A549 cell nuclear extracts
were prepared and EMSA was performed using biotin end-labeled
double-stranded DNA probes prepared by annealing complemen-
tary oligonucleotides. The binding reactions were performed using
the LightShift Chemiluminescent EMSA Kit (Pierce, Rockford,
IL) and conducted according to the manufacturer’s protocol. The
competition assay utilized a 200-fold excess of unlabeled probe
during the EMSA binding reaction. The gel-supershift assay
included incubation of the nuclear extracts (12 mg) with the hot
probe for 30 min, addition of 2 mg of CTCF polyclonal antibody
(Upstate Biotechnology), or the negative control of 2 mg of E2F1
polyclonal antibody (Active Motif) or 2 mg of IgG polyclonal
antibody (Upstate Biotechnology) in the binding reaction, and
30 min incubation at RT. Binding mixtures were loaded on a 4%
native polyacrylamide TBE gel in 0.56TBE, and gels were run at
100 V for 2 hour at room temperature. After electrophoresis, the
DNA-protein complexes were transferred onto nylon positively
charged membranes and detected using chemiluminescence
reagent (Pierce).
Luciferase reporter gene analysis
The E2F1 binding sites were identified using the transcription
factor search program PROMO [29]. Promoter sequences of
RASSF1A were cloned by PCR from IMR90 normal lung cell
DNA. Primer pairs used for PCR (2363 to +148 bp) [30] were
shown in Table S1. The fragment was cloned into the pGL4
luciferase reporter vector (Promega). Mutations in E2F1 binding
sites of RASSF1A gene were generated by QuickChange site-
directed mutagenesis kit (Stratagene, La Jolla, CA) using the
specific primers as: Mut-1, Mut-2 and Mut-3 (Table S1). CL1-1
cell line was co-transfected with 1 mg of the constructs and 2 mgo f
the pCMV-SPORT6-E2F1 expression vector (Open Biosystems)
using ExGen 500 in vitro transfection reagent (Fermentas). After
24 hours, the expression of luciferase gene was determined and
normalized by Dual-Luciferase reporter assay (Promega).
RASSF1A & BLU in Lung Cancer
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The statistical analyses of promoter methylation, RNA/protein
expression, patient survival and tumor characteristics of 76
patients were performed using SPSS program (SPSS Inc.,
Headquarters Chicago, IL, USA). Comparisons were made using
Chi-square test. The correlation between the MSO methylation
level and the mRNA expression level in 32 lung cancer patients
was calculated using t-test. P#0.05 were considered to be
statistically significant.
Results
Potential transcriptionally important CpGs in RASSF1A
and BLU gene of lung cancer patients
We examined the association between CpG methylation and
RNA expression of RASSF1A and BLU genes of 32 primary
NSCLC tumor samples to identify the CpG sites that were
hypermethylated and correlated with low transcriptional level. We
used the MSO array to assess methylation profiles of RASSF1A and
BLU CpG island regions in lung cancer patients. Preparation of
MSO arrays was carried out essentially as described previously
[27]. The 33 CpG sites of RASSF1A gene and the 38 CpG sites of
BLU gene within the CpG island were each examined with a
distinct group of 20 oligonucleotide probes. Genomic maps of the
RASSF1A and BLU CpG sites were shown in Fig. 1A. The
representative MSO figures are shown in Fig. S1. The average
methylation percentage at each CpG region was calculated for all
patients. CpG regions that were heavily methylated in all patients
were excluded since we could not distinguish their transcriptional
importance. The patients were ranked by average methylation
percentage in the remaining non-excluded CpG regions. The
heavily methylated and lightly methylated patients were separated
by a cut-off value which was determined by the mean methylation
percentage of potential transcriptionally important CpG sites for
the RASSF1A and BLU genes (Fig. 1B, 1C). To establish the
relationship between DNA methylation and gene expression, semi-
quantitative RT-PCR with optimized cycle number was conduct-
ed on 32 primary lung tumors (Fig. 1B, 1C). Using t-test, we found
that RASSF1A gene exhibited a strikingly significant difference in
mRNA expression pattern between the samples with heavily
methylated CpG regions and samples with lightly methylated CpG
regions (P=0.002), while the expression pattern of BLU gene was
only modestly different between these heavily and lightly
methylated groups (P=0.065). The 8 CpG regions correlating
with distinct transcription patterns of RASSF1A were located in the
proximal promoter and exon 1 region. The 11 CpG regions of
BLU were located in the proximal promoter and the distal region
of exon 1 (Fig. 1A).
E2F1 binds to the RASSF1A promoter at potential
transcriptionally important CpGs
To further investigate gene expression, RASSF1A and BLU
transcripts were analyzed in MRC5 and IMR90 normal lung cell
lines and three lung cancer cell lines (A549, CL1-0, and H1299) by
semi-quantitative RT-PCR. Both genes were expressed in MRC5
and IMR90, but neither was expressed in A549 and CL1-0
(Fig. 2A). Interestingly, H1299 cell line demonstrated a discordant
expression between BLU gene and RASSF1A gene. Qiu et al.
demonstrated that the BLU promoter was regulated by E2F1
binding, which was impaired by hypermethylation [24]. We thus
compared the potential transcriptionally important CpG sites that
we had identified with the E2F1 binding site identified by Qiu et al.
[24]. The data revealed that the CpG sites located at 263/
256 bp matched the consensus E2F1 binding site [24], and
indicated E2F1 binding sites were near important CpG sites in the
BLU gene.
In addition, we identified three putative E2F1-binding sites at
2150/2143, 25/+3 and +13/+23 bp within the RASSF1A CpG
island. They were potential transcriptionally important CpG sites
according to the MSO array results (upper panel of Fig. 1A). To
detect E2F1 binding to these sites, we performed the chromatin
immunoprecipitation (ChIP)-PCR assay using the E2F antibody
and primers designed to amplify specific fragments from 2220 to
+116 bp and 2330 to +58 bp in RASSF1A and BLU genes,
respectively (Fig. 1A). E2F1 bound to RASSF1A and BLU genes in
the MRC5 normal cell line, but not in A549 tumor cell line
(Fig. 2B). To investigate whether exclusion of E2F1 induced the
remodeling of chromatin structure in the promoter of RASSF1A
and BLU loci and led to a transcriptionally non-permissive state,
MRC5 normal lung cell line and A549 lung cancer cell lines were
analyzed by ChIP-PCR. ChIP was performed with antibody
against anti-acetylated histone H3 (K9Ac), which recognized
acetylated chromatin structure. The RASSF1A and BLU CpG
islands were acetylated in MRC5 and deacetylated in A549. These
data suggested that chromatin structure is more compact in the
A549 cancer cell line than in the MRC5 normal cell line (Fig. 2C).
In addition, loss of E2F1 binding to RASSF1A in A549 cancer cell
lines correlated with DNA methylation (Fig. 2D). In the luciferase
activity assay, mutation in E2F1 binding site at 2150/2143 bp
(Mut-1), 25/+3 bp (Mut-2), +13/+23 bp (Mut-3), and all E2F1
sites (Mut-1.2.3) within the RASSF1A promoter reduced the
promoter activity (Fig. 2E). These results demonstrated that
potential transcriptionally important CpG sites of RASSF1A were
bound by E2F1 transcription factor and E2F1 played a role in the
activation of the RASSF1A gene expression.
Association between promoter methylation status and
expression levels of RASSF1A and BLU
To determine whether there was an association between
promoter methylation status, protein and mRNA levels of
RASSF1A and BLU, 69 NSCLC primary tumors (including 32
patients who had been analyzed by MSO) were assessed by
immunohistochemistry (Fig. 3A), multiplex semi-quantitative RT-
PCR (Fig. 3B) and methylation-specific PCR (Fig. 3C) assays.
Immunohistochemical staining data indicated that 58.0% (40/69)
and 37.9% (25/66) of tumors showed an absence or low
expression of RASSF1A and BLU proteins, respectively. Semi-
quantitative RT-PCR showed the decrease or absence of RASSF1A
and BLU transcripts in 40.6% (28/69) and 50.0% (33/66) tumors,
respectively. Methylation-specific PCR (MSP) revealed promoter
hypermethylation of RASSF1A and BLU in 60.6% (40/66) and
48.4% (31/64) tumors, respectively. Cross-tabulation analysis
examined the relationship between the methylation status and
expression data using the Pearson’s x
2 test. Aberrantly low protein
expression was significantly associated with low mRNA transcript
(RASSF1A, P=0.036; BLU, P=0.048). Lack of mRNA expres-
sion was significantly associated with promoter methylation
(RASSF1A, P=0.012; BLU, P=0.036) (Fig. 3D). 43 patients were
examined for mRNA expression using quantitative RT-PCR
(qRT-PCR). The mRNA level detected by qRT-PCR correlated
with methylation levels revealed by MSP (Fig. S2) validating the
mRNA level detected by the semi-quantitative RT-PCR. Impor-
tantly, although RASSF1A and BLU are two tandem head-to-tail
genes located at 3p21.3, the methylation status of the RASSF1A
gene did not necessarily correlate with the BLU gene (Fig. 3E),
suggesting that there was no regional effect between these two
closely located genes.
RASSF1A & BLU in Lung Cancer
PLoS ONE | www.plosone.org 5 September 2010 | Volume 5 | Issue 9 | e12847Figure 2. E2F1 bound to the RASSF1A promoter at potential transcriptionally important CpGs. (A) RT-PCR analysis for RASSF1A and BLU
gene expressions in MRC5 and IMR90 normal cells and three cancer cell lines (A549, CL1-0, and H1299). GAPDH was amplified as an internal control.
(B) ChIP-PCR analysis for E2F1 binding to RASSF1A and BLU sequences in MRC5 normal cell and A549 cancer cell line. The binding of E2F1 to RASSF1A
and BLU promoters was observed in MRC5 cell line. ‘‘In’’, total input DNA; ‘‘E2F’’, DNA-protein complex precipitated by anti-E2F1; ‘‘IgG’’, DNA-protein
complex precipitated by rabbit IgG; and ‘‘No’’, no antibody. (C) ChIP assay with anti-acetylated histone H3 for RASSF1A, BLU and GAPDH loci. ‘‘K9Ac’’,
DNA-protein complex precipitated by anti-acetylated histone H3. (D) Methylation status of E2F1 binding sites in RASSF1A gene was assessed by MSP
in MRC5 normal cell and four cancer cell lines. U: unmethylated gene; M: methylated gene. SssI methyltransferase-treated MRC5 DNA was used as
methylation positive control. (E) Relative luciferase activities of different E2F1 mutated constructs are shown on the right side as bars in the bar chart,
with the structure of each construct shown on the left side. Luc: luciferase gene sequence. E2F1-expression vector was cotransfected with different
E2F1 binding sites mutated constructs (mutation sites shown as black circles).
doi:10.1371/journal.pone.0012847.g002
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elements) between RASSF1A and BLU genes
An insulator’s function as a barrier against effects from
surrounding domains requires association with the CTCF protein
[31]. Since we did not find significant correlations of methylation
status between RASSF1A and BLU in the corresponding patients
(Fig. 3E), we speculated that there might be CTCF binding sites
between RASSF1A and BLU genes. Using the CTCF binding site
database (CTCFBSDB) (http://insulatordb.utmem.edu), putative
CTCF binding sites were identified in exon 7 (CTCF-1), intron 8
(CTCF-2), and intron 11 (CTCF-3) of the BLU gene. To
determine whether CTCF bound to these regions between
RASSF1A and BLU genes, we conducted EMSA with probes
carrying wild-type and mutant CTCF binding sites of BLU gene.
The biotin-labeled probes (hot probes) were incubated with A549
nuclear extract and analyzed on a polyacrylamide gel. The
complexes were observed with band shift in wild-type hot probe
(lane 2 in Fig. 4A), but showed weak binding in mutant hot probe
sample (lane 4 in Fig. 4A). Specificity of binding was determined
by competition with an excess of the unlabeled wild-type probe
(lane 3 in Fig. 4A). To further corroborate the band shift
observations, gel-supershift analysis was performed with a
polyclonal antibody of CTCF, and a super-shifted band was
detected (lane 5 in Fig. 4A). In addition, CTCF bound to the
segment of the human apoB gene (lanes 6 and 7 in Fig. 4A) as the
positive control [32] and a rabbit IgG binding as the negative
control of gel-supershift analysis (Fig. S3) in EMSA. These EMSA
results suggested that CTCF formed complexes with three CTCF
binding sites in the BLU genes. Moreover, ChIP analysis was
performed to verify the in vivo association of CTCF to the BLU
gene. c-Myc gene was included as a positive control for CTCF
binding [33]. ChIP-PCR results indicated that CTCF protein
bound to the insulator located between the RASSF1A and BLU loci
in the IMR90 normal cells but not the H1299 (Fig. 4B), A549, and
CL1-0 cancer cells (Fig. S4A).
Distinct methylation and chromatin boundaries
separated by the CTCF binding domain in cell lines and
lung cancer patients
If the CTCF binding site within BLU gene indeed acted as an
insulator between independently controlled methylation domains,
patients showing hypermethylation of the BLU promoter and lack
of methylation in the RASSF1A promoter (or vice versa) should
display distinct methylation boundaries separated by the CTCF
binding domains. Therefore, we performed direct bisulfite DNA
sequencing of the regions flanking the three CTCF binding sites
within BLU gene from such NSCLC patients (i.e. patients 30, 42, 4
and 15 selected from Fig. 1B and 1C) as well as IMR90 normal
lung cell line and H1299 lung cancer cell line. The upstream and
downstream regions for three CTCF binding sites contained 1062
base pairs (spanning CpG site 266 to 254, relative to the
RASSF1A transcription start site) and 657 base pairs (spanning
CpG site 228 to +14) of PCR amplicon, respectively. Bisulfite
sequencing revealed a distinct methylation boundary separated by
the CTCF binding domains in IMR90 normal lung cell line and
patients 30 and 42 (Fig. 5A). Furthermore, the RASSF1A
expression status examining by semi-quantitative multiplex RT-
PCR correlated with RASSF1A promoter methylation status in all
samples examined (Fig. 5A and 5B). The gene expression status of
BLU also correlated with promoter methylation status (Fig. 1C and
Fig. 5B). In addition, the chromatin structure from each side
separated by the presumable insulator sequence was examined for
acetylated histone H3 (H3-K9Ac, a histone mark for open
chromatin) and tri-methylated histone H3 (H3-K27M, a histone
mark for condensed chromatin) in IMR90 and H1299 cell lines.
IMR90 cells which had CTCF binding showed a distinct
chromatin structure separated by the insulator sequence, whereas
H1299 cells without CTCF binding showed a concordant
chromatin structure (Fig. 6A). Taken together, these data
suggested that the CTCF binding site within BLU gene may act
as a barrier.
To investigate whether restoration of CTCF binding could
change the chromatin structure separated by the presumable
insulator sequence in H1299 lung cancer cells, we treated H1299
cells with both the DNA demethylating agent AZA and the
HDAC inhibitor TSA. We subsequently exogenously overex-
pressed CTCF. A ChIP-PCR analysis was performed to detect
CTCF binding at 96 hours post-CTCF overexpression. The data
indicated that CTCF binding was restored (the lower panel of
Fig. 6B). In addition, the chromatin structure of the region located
downstream of CTCF binding sites in treated H1299 cells was
converted to the pattern seen in normal cell (Fig. 6A and the upper
panel of 6B). These data suggested that restoration of CTCF
binding to the putative insulator prevented spreading of the
repressive chromatin marks past the insulator sequence to
downstream RASSF1A promoter sequences in the H1299 cancer
cells that overexpressed CTCF.
Discussion
Our study identified the potential transcriptionally important
CpG sites in RASSF1A and BLU genes for the first time, and
verified the binding of E2F1 to these CpG sites. In addition, we
provided compelling evidence that CTCF binding to an insulator
located downstream of the BLU gene provides a barrier activity
within separate epigenetic domains and regulates the expression of
the juxtaposed BLU and RASSF1A genes.
Figure 3. Protein and mRNA expression and promoter methylation assays for RASSF1A and BLU genes. (A) Immunohistochemical
analysis of RASSF1A and BLU proteins in paraffin-embedded sections of tumor and normal specimens of representative NSCLC patients. The RASSF1A
protein expression status for three samples are marked as panel (a), (b), and (c) and the BLU protein expression status for the other three samples are
marked as panel (d), (e), and (f). The cells that exhibited brown color staining in cytoplasm were considered positive for protein expression (patients a
and d). Negative immunoreactivity of RASSF1A and BLU was found in two patients (b and e). The histologies in (a) and (d) are adenocarcinomas, (b)
and (e) are squamous cell carcinomas, and (c) and (f) are normal lung tissues. Original magnification x200. (B) Representative examples of semi-
quantitative multiplex RT-PCR analysis of the RASSF1A and BLU genes in lung cancer patients. GAPDH was used as the internal control for the analysis.
N and T represent the paired normal and tumor lung cells from the same patient. (C) Methylation status of RASSF1A and BLU genes were assessed by
MSP in tumor (T) and matched normal (N) lung samples. (D) Concordance analysis between protein expression, mRNA expression, and methylation
status of RASSF1A and BLU genes. Y-axis represents the percentage of cases; X-axis represents the type of comparison. Concordance analysis for
RASSF1A and BLU was depicted as percentage. ‘‘+’’ indicated positive protein expression, positive mRNA expression, and DNA hypermethylation, as
opposed to ‘‘–’’, which indicated a negative result. Numbers above the bars indicated the percentage in the total concordant group (gray column)
and discordant group (white column). P #0.05 was considered to be statistically significant and was labeled with *. (E) Correlation analysis of
methylation status between RASSF1A and BLU. Numbers above the bars indicated the percentage in the total concordant group (gray column) and
discordant group (white column).
doi:10.1371/journal.pone.0012847.g003
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er regions of TSGs is becoming a common phenomenon in
tumorigenesis. The MSO array can be applied to map methylation
CpG sites within the CpG island of a candidate gene in normal or
tumor DNA. This method was used for mapping methylation
changes at individual CpG site in CpG island loci of ERa,
p16INK4A, and hMLH1 genes in different cancers [26,34,35]. In
this paper, we combined MSO array methylation data and RNA
expression status from lung cancer patients to identify potential
transcriptionally important CpG sites of RASSF1A and BLU
promoters (Fig. 1). When these potential transcriptionally important
CpG sites were hypermethylated, transcription factors such as E2F
failed to bind to the promoter and the hypermethylation hindered
gene transcription and expression (Fig. 2). However, some of
patients showed discordance between methylation level and
transcription level of potential transcriptionally important CpG
regions. These discordant results may be due to the presence of
severaldistinct tumor subpopulations, one of which has methylation
and does not express the mRNA, the others having no methylation
and expressing the mRNA. Alternatively, methylation of only one
allele in these tumors may result in the positive mRNA expression
observed.Futurestudiesthatanalyzetherelationshipofmethylation
of each CpG site with expression levels by luciferase activity assay
can further decipher regulatory mechanisms.
E2F1 transcription factor failed to bind to the recognition
sequence that contained methylated CpG dinucleotides [36]. In
Figure 4. There were three CTCF binding sites between RASSF1A and BLU genes. (A) Genomic map on the top shows the position of three
putative insulator regions (CTCF-1, CTCF-2, and CTCF-3) between BLU and RASSF1A gene loci examined in EMSA. The region analyzed for ChIP-PCR
assay is as indicated. Bottom figure shows three oligonucleotide probes (CTCF-1, CTCF-2, and CTCF-3) containing putative CTCF binding sites in the
BLU gene were synthesized and used for EMSA analysis. The biotin-labeled (hot probes) wild-type (Wt) and mutant (mut) oligonucleotide fragments
were incubated with A549 nuclear extract and electrophoresed on 4% polyacrylamide gel (lanes 2 and 4). Competition experiments (lane 3) utilized a
200-fold excess of unlabelled wild-type sequences to demonstrate the specificity of each binding reaction. In the presence of anti-CTCF antibody, a
supershift complex formed (lane 5). The human apoB gene (lanes 6 and 7) was the positive control for EMSA. Arrows indicated the band shift and
super-shift of specific protein–DNA complexes. The sequence information for EMSA probes was given in Table S1. (B) ChIP-PCR assay for CTCF
binding between RASSF1A and BLU genes in IMR90 and H1299 cell lines. ‘‘In’’, total input DNA; ‘‘CTCF’’, DNA-protein complex pulled down by anti-
CTCF; ‘‘IgG’’, DNA-protein complex pulled down by rabbit IgG; and ‘‘No’’, no antibody. c-Myc served as a positive control for CTCF binding. D3D1568
microsatellite sequence served as a negative control for CTCF binding. Data represented are selected from three independent experiments.
doi:10.1371/journal.pone.0012847.g004
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the potential transcriptionally important CpG sites of RASSF1A
promoter. We also confirmed that hypermethylation at the CpGs
located within the E2F1 binding sites blocked E2F1 binding and
suppressed RASSF1A expression in A549 cancer cell line (Fig. 2D).
In addition, exclusion of E2F1 binding may result in the
remodeling of chromatin in the region into a transcriptionally
non-permissive state [37], in agreement with the compact
chromatin structure of RASSF1A and BLU promoters in the
A549 cell (Fig. 2C). However, site-directed mutagenesis of E2F
sites of the RASSF1A promoter only partially reduced its promoter
activity, which suggested that other activators such as SP1 may be
involved in the transcriptional activation of RASSF1A gene [30].
Many studies demonstrate hypermethylation of the RASSF1A
and BLU gene promoters and low mRNA expression in various
cancers [3,10,24]. However, most studies show no correlation
between low RASSF1A and BLU mRNA expression in cancers.
Our study demonstrated that there were no correlations of
methylation status (Fig. 3E) or expression status (Fig. S5) between
these two genes in NSCLC patients. These results suggested that
there was no regional effect between these two head-to-tail located
genes. Insulators are DNA elements that prevent inappropriate
interactions between neighboring chromatin domains, and CTCF
is a major insulator binding protein in the vertebrates that mediate
the insulator activity. CTCF is a critical transcription factor which
is involved in transcription activation and repression by binding
the chromatin insulators [38]. In addition, CTCF also has barrier
function to prevent spreading of heterochromatin structure and
DNA methylation which plays a critical role in maintaining
methylation-free zones [39,40]. In recent study, Witcher and
Emerson identified CTCF binding to a region (,1.8 kb) upstream
of the RASSF1A promoter [33], which was further refined to exon
Figure 5. Distinct methylation boundaries separated by the CTCF binding domain. (A) Bisulfite sequencing results revealed a distinct
methylation boundary separated by the CTCF binding domains in IMR90, H1299 cell line, and four lung cancer patients. CpG sites were designed as
266 to +14 (corresponding to nucleotide numbers from 22314 to +137 bp) in which the first CpG site was defined as +1 and corresponded to the
RASSF1A transcriptional start site. The red dots below the genomic map indicated the locations of all CpG sites examined. Black box: methylated CpG;
write box: unmethylated CpG. CTCF sites were indicated by hatched boxes. The primers used for bisulfite sequencing are shown at the bottom. (B)
Semi-quantitative multiplex RT-PCR analysis of the RASSF1A and BLU genes in IMR90, H1299 cell line, and four lung cancer patients which were
analyzed by bisulfite sequencing. GAPDH was used as the internal control for the analysis.
doi:10.1371/journal.pone.0012847.g005
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sequencing and ChIP-PCR results revealed distinct methylation
and chromatin structure boundaries separated by the CTCF
binding domains which are located at the 39 end of BLU gene in
IMR90 normal cell line (Fig. 5A and 6A). Furthermore, CTCF
unbound insulator sequence allowed encroachment of methylation
and heterochromatin structure into downstream RASSF1A pro-
moter which hindered its transcriptional activity in H1299 cancer
cell (Fig. 4B and Fig. 5). However, the BLU gene expression does
not correlate with CTCF binding status (Fig. 5), because the
transcriptional activity of this gene is regulated by promoter
methylation (Fig. 2A and Fig. S4). These data suggested that
CTCF binding to the insulator prevented spreading of DNA
methylation and post-translational modifications of chromatin
from the BLU locus to the RASSF1A gene promoter. In addition,
H1299 cancer cell treated with demethylating reagent (AZA),
histone deacetylase inhibitor (TSA) and overexpression of CTCF
led to restoration of CTCF binding as well as a change of
chromatin structure separated by the presumable insulator
sequence between RASSF1A and BLU loci (Fig. 6B). These results
indicated that the boundary function is restored in H1299 cancer
cell.
It was interesting that AZA and TSA treatment of H1299
cancer cell changed the chromatin structure in downstream
sequences between BLU and RASSF1A genes, but not upstream of
the CTCF binding sites (Fig. 6A and the upper panel of 6B).
Recently, MYC protein recruited the PRC2/EZH2/DNMT3B
complex to bind to the RASSF1A promoter, which led to RASSF1A
gene silencing by promoter CpGs hypermethylation and con-
densed chromatin in cancer cell [41]. EZH2, a subunit of
Polycomb repressive complex 2 (PRC2), is a histone methyltrans-
ferase that methylates H3K27 [42]. PRC2-mediated transcrip-
tional silencing has been impeded by the histone deacetylase
inhibitor TSA [43]. Our results that AZA and TSA treated H1299
cancer cell changed the chromatin structure nearby the RASSF1A
promoter, but not upstream of the CTCF binding sites between
RASSF1A and BLU loci supported their mechanisms [41–43].
In summary, we used MSO array and mRNA expression data
to identify the potential transcriptionally important CpG sites of
RASSF1A or BLU gene promoter in NSCLC patients. We also
discovered that the potential transcriptionally important CpG sites
of RASSF1A were bound by E2F1 transcription factor. We
provided compelling evidence that there are CTCF binding sites
between RASSF1A and BLU genes, and occupied CTCF sites
prevent the encroachment of methylation and repressive chroma-
tin from the neighboring gene. Although RASSF1A and BLU genes
are tandem head-to-tail genes located at 3p21.3 that contains a
171 bp intervening sequence, CTCF binding to the insulator
sequence located at the 39 end of BLU gene, but upstream of the
RASSF1A promoter, may provide barrier activity between these
two loci (Fig. 6C). Further refined mapping of CTCF binding
region by ChIP-sequencing and identification of other proteins
involved in insulator function are worthy of investigation.
Supporting Information
Figure S1 Representative MSO array figures. (A) Standardiza-
tion curve for MSO assays. Upper panel, the series of MSO
hybridization were performed with mixed samples containing 0,
33, 66, and 100% of in vitro-methylated DNA and amplified by
PCR for the RASSF1A CpG island. The Cy5 fluorescent dye was
added to the 39 end of amplified fragments, and signals of the
methylated (M) and unmethylated (U) probes for RASSF1A CpG
region #4 were shown, which reflected the indicated percentage
of methylation. Lower panel, standard curve for measuring
methylation level for RASSF1A CpG region #4 was shown.
The intensity ratios (Y-axis) represented signal intensities of M/
M+U. The linear distribution showed that measurements of the
different mixtures were easily distinguished and used to determine
the methylation level in the same CpG region for the patient
samples. (B) Hybridization of three lung tumor samples to MSO
Figure 6. Chromatin structure assays of upstream and down-
stream for CTCF binding domain. (A) Chromatin structure was
examined by ChIP-PCR at upstream and downstream of CTCF binding
sites using the K9Ac (for open chromatin) and K27M (for compacted
chromatin) antibodies in IMR90 and H1299 cells. (B) ChIP-PCR for
chromatin structure at upstream and downstream of CTCF binding sites
(upper panel) and ChIP-PCR for CTCF binding (lower panel) after drug
(AZA and TSA) treatments and CTCF exogenous expression in H1299
cell are shown. ‘‘In’’, total input DNA; ‘‘CTCF’’, DNA-protein complex
precipitated by anti-CTCF; ‘‘IgG’’, DNA-protein complex precipitated by
rabbit IgG; and ‘‘No’’, no antibody. c-Myc served as a positive control.
Data represented are selected from three independent experiments. (C)
Models for CTCF binding to insulator sequence and their effect on
hypermethylation of the downstream RASSF1A promoter. Top diagram:
CTCF binding to insulator sequence and prevention of encroachment of
hypermethylation in RASSF1A promoter in normal lung cells. Bottom
diagram: unbound insulator sequence allowed encroachment of
methylation and heterochromatin structure into downstream RASSF1A
promoter which hindered its transcriptional activity.
doi:10.1371/journal.pone.0012847.g006
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PLoS ONE | www.plosone.org 11 September 2010 | Volume 5 | Issue 9 | e12847microarray and images corresponding to the RASSF1A CpG
region #4. Patient number 45 showed 0% methylation, but
patient #16 and #9 displayed 58.4% and 79.3% methylation,
respectively, based on the intensity ratios calculated from the
standard curve.
Found at: doi:10.1371/journal.pone.0012847.s001 (0.09 MB
DOC)
Figure S2 Concordance analysis between mRNA expression
(qRT-PCR) and methylation status (MSP) of RASSF1A and BLU
genes. Y-axis represents the percentage of cases; X-axis represents
the type of comparison. ‘‘+’’ indicates positive mRNA expression
and DNA hypermethylation, as opposed to ‘‘2’’, which indicates a
negative result. Numbers above the bars indicate the percentage in
the total concordant group (gray column) and discordant group
(white column). P values are as indicated.
Found at: doi:10.1371/journal.pone.0012847.s002 (0.06 MB
DOC)
Figure S3 Three CTCF binding sites between RASSF1A and
BLU genes by EMSA analysis. Three oligonucleotide probes (1, 2,
and 3) containing putative CTCF binding sites in the BLU gene
were synthesized and used for EMSA analysis. The biotin-labeled
(hot probes) wild-type (Wt) oligonucleotide fragments were
incubated with A549 nuclear extract and electrophoresed on 4%
polyacrylamide gel. In the presence of anti-E2F1 antibody (lanes 1
to 3) and anti-IgG antibody (lanes 4 to 6), no super-shift complex
was formed. The human apoB gene (lane 7) was the positive
control for CTCF binding. Arrows indicated the band shift of
specific protein-DNA complexes. The sequence information for
EMSA probes is given in Table S1.
Found at: doi:10.1371/journal.pone.0012847.s003 (0.17 MB
DOC)
Figure S4 CTCF binding assay and promoter methylation assay
of RASSF1A and BLU genes in A549 and CL1-0 cancer cell lines.
(A) ChIP-PCR assay for CTCF binding between RASSF1A and
BLU genes in A549 and CL1-0 cell lines. ‘‘In’’, total input DNA;
‘‘CTCF’’, DNA-protein complex pulled down by anti-CTCF;
‘‘IgG’’, DNA-protein complex pulled down with rabbit IgG; and
‘‘No’’, no antibody. c-Myc served as a positive control for CTCF
binding. D3D1568 microsatellite sequence served as a negative
control for CTCF binding. (B) Methylation status of RASSF1A
and BLU genes were assessed by MSP in MRC5 normal cell,
A549 and CL1-0 cancer cell lines. U: unmethylated gene; M:
methylated gene. SssI methyltransferase-treated MRC5 DNA was
used as methylation positive control.
Found at: doi:10.1371/journal.pone.0012847.s004 (0.16 MB
DOC)
Figure S5 Correlation analysis of mRNA and protein expression
between RASSF1A and BLU. Y-axis: the percentage of cases; X-
axis: the type of comparison. ‘‘+’’ indicated positive mRNA
expression and protein expression, as opposed to ‘‘2’’, which
indicated a negative result. Numbers above the bars indicate the
percentage in the total concordant group (gray column) and
discordant group (white column). P values were compared results
of RASSF1A with BLU.
Found at: doi:10.1371/journal.pone.0012847.s005 (0.05 MB
DOC)
Table S1 Primer sequences, annealing temperature, and
number of cycles in PCR reaction.
Found at: doi:10.1371/journal.pone.0012847.s006 (0.11 MB
DOC)
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